ArgonautArgonautArgonautArgonaut
  • About Us
    • Business Model
    • Regulation
    • Community
    • Jason and the Argonauts
    • Disclaimer and Disclosure
    • COVID-19 Visitor Requirements
  • Corporate Finance
  • Stockbroking & Research
    • Stockbroking
    • Research
    • Best Execution Policy
    • Administration Forms
    • Open an Account
  • Special Situations
  • News
    • Latest News
    • Morning Notes
    • Latest Research
  • Contact
    • Careers
      • Advisers
      • Graduate Program
      • Internship Program

Botanix (BOT) – Encouraging Results Lead To A Valuation Update

    Home Latest Research Botanix (BOT) – Encouraging Results Lead To A Valuation Update
    NextPrevious

    Botanix (BOT) – Encouraging Results Lead To A Valuation Update

    By Wendy McEvoy | Latest Research | 0 comment | 16 July, 2019 | 0

    We have updated our valuation for Botanix by including a value for the anti-microbial BTX1801. There are now two independent studies showing efficacy, and we expect the next steps to be human trials with a Phase 1 safety study. We have also updated our Psoriasis (BTX1308) valuation on the basis that new data has emerged, showing a larger addressable market with a very strong CAGR than we originally assumed. BTX1503 and BTX1204 have also been updated based on the current study spend. We maintain our SPEC BUY recommendation and increase our target price to $0.29 from $0.20.

    To access the full report please log in under the Client Area at the bottom of this page.

    Argonaut’s Client Area allows you to view delayed share prices, access Argonaut’s wealth of Research as well as create custom portfolios and set up company watch lists.

    If you would like to access our research please contact us to create an account.

    No tags.

    Related Posts

    • New Research – Global Lithium (GL1) – Manna From Heaven

      By Wendy McEvoy | 0 comment

      We provide a major update to our Global Lithium (GL1) research. GL1’s share price has performed well since IPO in mid-2021. The Company is progressing Resource drill outs at the 100% owned Marble Bar andRead more

    • Ausgold Limited (AUC) – Study a Starting Point

      By Wendy McEvoy | 0 comment

      Broad brushes, Ausgold’s Katanning PFS published last week was in line with our expectations. Overall, the demonstration of the ability to front-end high-grades in the mine plan means that Katanning outperforms our previous mining-scenario weRead more

    • Good Drinks (GDA) – FY22 Preliminary Results

      By Wendy McEvoy | 0 comment

      The FY22 EBITDA result was in line with our thinking, and GDA confirmed a step change in earnings in FY23 on the back of the new Venues and Agency segments. This will be applied toRead more

    • WA Gold Advanced Explorers – March 2022 Quarter Review

      By Wendy McEvoy | 0 comment

      Argonaut has reviewed quarterly results for select WA gold advanced explorers. This groups March Q lull in spending was short-lived with previous expenditure highs eclipsed. Spend will have to slow down unless strong results areRead more

    • Northern Star Resources (NST) – KCGM Site Visit

      By Wendy McEvoy | 0 comment

      Northern Star (NST) expects less gold production in in FY23 and FY24 than we had forecast as KCGM works to re-establish access to higher grade areas in the pit. The ramp-up in gold production fromRead more

    NextPrevious
    • About Us
      • Business Model
      • Regulation
      • Community
      • Jason and the Argonauts
      • Disclaimer and Disclosure
      • COVID-19 Visitor Requirements
    • Corporate Finance
    • Stockbroking & Research
      • Stockbroking
      • Research
      • Best Execution Policy
      • Administration Forms
      • Open an Account
    • Special Situations
    • News
      • Latest News
      • Morning Notes
      • Latest Research
    • Contact
      • Careers
        • Advisers
        • Graduate Program
        • Internship Program
    Argonaut

    Argonaut | The Natural Choice in Resources.
    © 2022 Argonaut.

    Corporate Finance
    Stockbroking & Research
    Contact Us

    Argonaut | Perth

    Level 30, Allendale Square, 77 St Georges Terrace Perth, WA, 6000 Australia

    clientservices@argonaut.com

    ABN 72 108 330 650

    Argonaut | Login

    Client Area Help
    Register for Access to Client Area
    Privacy Policy
    Financial Services Guide 
    Website Disclaimer

    Copyright 2021 | Website ⚡ by Start Digital